Novartis Loses Bid To Make FDA Block Patent Term Extension
The U.S. Food and Drug Administration on Wednesday refused Novartis Gene Therapies' request to disqualify Regenxbio Inc. from getting a patent term extension — based on delays in the approval process...To view the full article, register now.
Already a subscriber? Click here to view full article